Sleep Apnea and Vascular Function
| Status: | Recruiting |
|---|---|
| Conditions: | Insomnia Sleep Studies |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 9/28/2017 |
| Start Date: | November 2012 |
| End Date: | November 2017 |
| Contact: | Somers_CPL Lab |
| Email: | CPL@mayo.edu |
Obstructive sleep apnea (OSA) is associated with endothelial dysfunction and the development
of cardiovascular disease. It is unclear how OSA results in endothelial dysfunction, but
given the association between OSA and obesity, adipose-derived hormones (adipokines) are
likely to be involved. Leptin, an adipokine upregulated in patients with OSA, has been shown
to be associated with deleterious effects on vascular function resulting in impaired
endothelial function. This proposal is directed at investigating the molecular mechanisms of
endothelial dysfunction in OSA patients. We hypothesize that endothelial dysfunction
associated with OSA is a result of molecular alterations within endothelial cells. As a part
of these studies we will look at NO signaling pathways in adipose tissue and microvessels
from normal and OSA subjects.
of cardiovascular disease. It is unclear how OSA results in endothelial dysfunction, but
given the association between OSA and obesity, adipose-derived hormones (adipokines) are
likely to be involved. Leptin, an adipokine upregulated in patients with OSA, has been shown
to be associated with deleterious effects on vascular function resulting in impaired
endothelial function. This proposal is directed at investigating the molecular mechanisms of
endothelial dysfunction in OSA patients. We hypothesize that endothelial dysfunction
associated with OSA is a result of molecular alterations within endothelial cells. As a part
of these studies we will look at NO signaling pathways in adipose tissue and microvessels
from normal and OSA subjects.
Inclusion Criteria:
- Non OSA, and newly diagnosed OSA subjects, naïve to CPAP treatment, aged 18-65 years,
with BMI less than or equal to 55 kg/m2, who are free of all chronic diseases
including diabetes, and cardiovascular diseases, will be recruited for our study.
Subjects with dyslipidemia and hypertension will be allowed to participate in the
study. Subjects taking anti-depressents, and anithypertensives will be allowed to
participate in the study. Also, subjects taking beta blockers and beta agonists will
be allowed to participate in the study.
If a subject is on aspirin or any other anti-inflammatory medication but free of known
vascular disease and depending on the indication, the study doctor may ask the subject to
suspend aspirin or anti-inflammatory therapy for 7 days prior to participation in the
study. In the event that the subjects does not stop the aspirin or other anti-inflammatory
medication, they will not be able to participate in the study because of the risk of
bleeding during the fat biopsy.
Exclusion Criteria:
- Body weight >450 pounds (204.5kg)
- Pregnancy.
- Anemic (hemoglobin <13.5 g/dL for men and <12.0 g/dL for women.
- Postmenopausal
- Smoking
- Use of chronic Medications (aspirin, statins, anti-inflammatory drugs)
We found this trial at
1
site
Click here to add this to my saved trials
